

GOVERNMENT OF INDIA
MINISTRY OF CHEMICALS AND FERTILIZERS
DEPARTMENT OF PHARMACEUTICALS

LOK SABHA
UNSTARRED QUESTION No. 1892
TO BE ANSWERED ON THE 06th DECEMBER, 2024

Upgradation of Pharmaceutical Industry

1892. Shri C N Annadurai:
Shri Navaskani K:
Shri Selvam G:

Will the Minister of **CHEMICALS AND FERTILIZERS** be pleased to state:

- (a) the primary objectives and implementation status of the Strengthening of Pharmaceutical Industry (SPI) scheme across the country;
- (b) the details of pharmaceutical companies, particularly MSMEs, that have benefited from the SPI scheme indicating the criteria for selecting beneficiaries;
- (c) whether the SPI scheme include provisions for upgrading pharmaceutical infrastructure, such as common facilities, if so, the details thereof;
- (d) whether a large number of pharmaceutical parks or clusters have been supported under the SPI scheme, if so, the details thereof;
- (e) the steps being taken under the SPI scheme to support the upgradation of technology in pharmaceutical units; and
- (f) the mechanisms that are in place to monitor the progress of the SPI scheme?

ANSWER

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS & FERTILIZERS
(SMT. ANUPRIYA PATEL)

(a): The SPI scheme is a Central Sector Scheme (CSS) with an outlay of Rs.500 Cr with the scheme period from FY 2021-22 to FY 2025-26.

Objectives of the SPI scheme are as follows:

- I. To strengthen the existing infrastructure facilities in order to make India a global leader in Pharma Sector by providing financial assistance to pharma clusters for creation of Common Facilities to improve the quality and ensure the sustainable growth of cluster;
- II. To upgrade the production facilities of Pharma units to meet up to date regulatory standards, by providing subsidy on reimbursement basis, which will enable them to obtain revised Schedule M and WHO_GMP certifications.
- III. To promote knowledge and awareness in and about the Pharmaceutical and Medical Devices Industry by taking up studies, building databases and bringing industry leaders, academia and policy makers together to share their knowledge and experience for overall development of Pharma and Medical Devices industry.

The Scheme has 3 components / sub-schemes:

- I. Assistance to Pharmaceutical Industry for Common Facilities (APICF)

- II. Revamped Pharmaceutical Technology Upgradation Assistance Scheme (RPTUAS)
- III. Pharmaceutical & Medical Devices Promotion and Development Scheme (PMPDS)

The implementation status of the three sub-schemes is as under :

I. Assistance to Pharmaceutical Industry for Common Facilities (APICF) :

- a) Outlay: Rs.178.40 Crore (out of which Rs. 20.15 Crore has already been utilised under old APICF)
- b) No. of projects which have been sanctioned assistance: 7
- c) Amount Sanctioned: Rs.121.46 Crore
- d) Amount Disbursed: Rs.62.47 Crore

II. Revamped Pharmaceutical Technology Upgradation Assistance Scheme (RPTUAS):

- a) Outlay: Rs.300.10 Crore
- b) No. of projects which have been sanctioned assistance: 62
- c) Amount Sanctioned: Rs. 59.55 Crore
- d) Amount Disbursed: Nil

III. Pharmaceutical & Medical Devices Promotion and Development Scheme (PMPDS):

- a) Outlay: Rs.21.50 Crore
- b) No. of studies which have been sanctioned assistance: 11
- c) Amount Sanctioned: Rs.1.16 Crore
- d) Amount Disbursed: Rs.0.88 Crore
- e) No. of reports finalised: 5

(b): The names of the beneficiaries which have been sanctioned assistance under RPTUAS scheme are given in the **Annexure**.

Criteria for selecting the beneficiaries are as under:

- i. Existing pharma units which require to upgrade to Revised Schedule M and WHO-GMP standards.
- ii. Existing Pharmaceutical manufacturing units having average annual turnover of less than Rs. 500 crore over the last 3 years.

(c): Under the sub-scheme APICF, the support is provided to strengthen the existing pharmaceutical clusters' capacity for their sustained growth by creating tangible assets as "Common Facilities".

Incentive under the scheme: The limit of incentive will be 70% of the approved project cost or Rs 20 cr., whichever is less, as per approval of SSC. In the case of Himalayan States and States in the North East Region, the grant-in-aid would be Rs. 20 Crore per Cluster or 90% of the project cost of the Common Infrastructure Facilities (CIF), whichever is less.

The illustrative list of eligible activities under this sub-scheme in order of priority is as under:

- i Research and Development Labs
- ii Testing Laboratory for Pharma Products

- iii Effluent Treatment Plants
- iv Logistic Centers
- v Training Centers

Under RPTUAS sub-scheme, the support is provided to existing Pharma units to upgrade the technological capabilities to Revised Schedule M/ WHO-GMP standards.

Incentive under the scheme : The rate of incentive under the scheme ranges from 10% to 20% (depending on the annual turnover of the Pharma unit) of the expenditure incurred on eligible activities subject to a maximum of Rs. 2 crores.

Expenditure incurred on below items would be considered for subsidy:

- a. Utilities (HVAC, Water, Steam)
- b. Clean Room Facility
- c. Testing Lab, Stability Chamber
- d. Effluent treatment/Waste Management
- e. Consultation/Certification Expenses
- f. Production Equipment
- g. Any other item with the recommendation of the Technical Committee

(d): Under API-CF sub scheme of SPI scheme, 07 projects have been approved from F.Y. 2022-23 to till date with the total Grant-in-aid of Rs. 121.46 crores out of which Grant-in-aid of Rs. 62.47 crores has already been released under the scheme.

(e): The Revamped Pharmaceutical Technology Upgradation Assistance Scheme (RPTUAS) sub-scheme of Strengthening of Pharmaceutical Industry (SPI) encourages units to upgrade the production facilities of existing Pharma & API manufacturing units having average sales turnover up to Rs. 500 Crore so as to meet national and international regulatory standards.

The objective of the scheme is to facilitate existing pharma units to upgrade to Revised Schedule M and WHO-GMP standards.

Under RPTUAS, support for existing pharma units is proposed in the form of incentive ranging from 10% to 20% subject to a maximum of Rs. 2 Crore under eligible activities listed out in the scheme guidelines. An outlay of 300.10 Cr has been earmarked under RPTUAS for the scheme period of five years.

(f): The Scheme is implemented through a Project Management Agency (PMA) which is responsible for providing secretarial, managerial and implementation support and carrying out other responsibilities as assigned by the Department from time to time. The scheme is periodically reviewed and monitored by the Scheme Steering Committee [headed by Secretary (Pharmaceuticals)] which also provides timely directions for effective implementation of the scheme.

Physical visits are also being done by the officials of Department and PMA for review/ effective monitoring of projects under the scheme. Periodic interactions are done with the applicants by the officials of Department and PMA.

Annexure

Statement referred to in reply to part (b) of the Lok Sabha Unstarred Question No. 1892 for answer on 06.12.2024

Applicants approved under RPTUAS sub-scheme (as on 05.12.2024)			
S. No.	Name of Applicant	Amount (in Rs. Lakh)	Nature of Entity (MSME/Non-MSME)
1	Dinakara Life Science Private Limited	200	MSME
2	Anuja Healthcare Limited	188.7	MSME
3	Ethix Health Care (HP)	97.46	MSME
4	Bennet Pharmaceuticals Limited	112.8	MSME
5	Maxwell Pharma (HP)	102.46	MSME
6	Ce Chem Pharmaceuticals Private Limited	120.75	MSME
7	M Sea Pharmaceuticals Private Limited (HP)	82	MSME
8	Park Pharmaceuticals (HP)	188.33	Non-MSME
9	Alapati Pharma	50.27	MSME
10	Sreepathi Pharmaceuticals Limited	105.84	MSME
11	BDR Lifesciences Pvt. Ltd.	168.62	Non-MSME
12	Sangharsh Lifecare Private Limited	177.98	MSME
13	Dano Vaccines & Biologicals Pvt Ltd	56.2	MSME
14	Pro-Pharma Care Pvt Ltd	114.68	MSME
15	Three B Healthcare Limited (HP)	109.4	MSME
16	Nandu Chemical Industries	60.93	MSME
17	Denis Chem Lab Ltd	66.91	MSME
18	Daffohils Laboratories Pvt Ltd	74.6	MSME
19	Auraya Healthcare Unit-Ii	102.83	MSME
20	Bakul Pharma Private Limited	111.45	MSME
21	Medoz Pharmaceuticals Pvt Ltd (HP)	90.39	MSME
22	Navil Laboratories Pvt Ltd	126.51	MSME
23	Unispeed Pharmaceuticals Private Limited (HP)	55.7	MSME
24	Pharma Force Lab (HP)	200	MSME
25	Virdev Intermediates Pvt Ltd	200	MSME
26	Magnum Chemi Gran Pvt Ltd	200	MSME
27	Velite Pharmaceuticals	35.56	MSME
28	Sirmour Remedies Pvt Ltd	167.21	MSME
29	Sarv Pharmaceuticals	52.5	MSME
30	Altis Finchem Private Limited	162.15	MSME
31	Mediforce Healthcare Pvt Ltd	22.76	MSME
32	Kentrech Laboratories Private Limited	76.68	MSME
33	Sanzyme Pvt Limited	69.53	MSME
34	SciTech Specialities Pvt Ltd	39.33	MSME
35	Talent Healthcare	126.35	MSME
36	Neha Life Science Private Limited	52.6	MSME
37	Systacare Remedies	11.07	Non-MSME
38	Prochem Pharmaceuticals Private Limited	79.65	MSME
39	Goish Remedies Limited	107.56	MSME
40	Saimirra Innopharm Private Limited	115.88	MSME
41	Alexi Pharmicia Pvt Ltd	65.39	MSME
42	Tosc International Private Limited	31.55	MSME
43	Vulcan Laboratories Private Limited	191	MSME
44	Vowcare Products	11.39	Non-MSME

45	Saurav Chemicals Limited	31.86	MSME
46	Vasa Pharmachem Private Limited	50.26	MSME
47	Arnav Research Laboratories	67.95	MSME
48	Murli Krishna Pharma pvt ltd	57.77	MSME
49	Biodeal Pharmaceuticals Limited	105.3	MSME
50	Zenith Drugs Limited	113.5	MSME
51	Nucare Laboratories India	82.37	MSME
52	Aqua Fine Injecta Pvt Ltd	33.79	MSME
53	Adrhim Pharmaceuticals Llp	75.71	MSME
54	Swati Chemicals	145.24	MSME
55	B. Sharda Pharma Pellets Private Limited	45.04	MSME
56	Emil Pharmaceutical Industries Private Ltd	200	MSME
57	Brit Lifescience	128.4	MSME
58	Srikem Laboratories Pvt Ltd	24.2	MSME
59	Protech Biosystems Pvt Ltd	85.97	MSME
60	Schon Pharmaceuticals Limited	97.4	MSME
61	Ornate Labs Pvt Ltd	3.94	MSME
62	Mendine Pharmaceuticals Pvt Ltd	23.52	MSME
Total		5955.19	
